Terms: = Breast cancer AND CEP17
233 results:
1. Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.
Peg V; Moline T; Roig M; Saruta Y; Cajal SRY
Diagn Pathol; 2024 Feb; 19(1):32. PubMed ID: 38360676
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.
Rönnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Breast Cancer Res; 2024 Feb; 26(1):24. PubMed ID: 38321542
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of an amplicon-based large panel next generation sequencing (NGS) assay with conventional testing methods for MET and HER2 amplification in lung and breast cancers.
Tay TKY; Tan GS; Lee SH; Sam XX; Lim TH; Ng JWK; Tan DSW; Lim TKH
Pathology; 2024 Apr; 56(3):325-333. PubMed ID: 38195375
[TBL] [Abstract] [Full Text] [Related]
4. A ddPCR platform based on a microfluidic chip with a dual-function flow-focusing structure for sample-to-result DNA quantification analysis.
Zhang X; Wang S; Wang J; Sun X; Xue J; Wang Z; Yang T; Weng L; Wang B; Luo G
Lab Chip; 2024 Feb; 24(4):738-750. PubMed ID: 38192250
[TBL] [Abstract] [Full Text] [Related]
5. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
[TBL] [Abstract] [Full Text] [Related]
6. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract] [Full Text] [Related]
7. Proposal to distinguish HER2-low from HER2-normal breast cancer by in situ hybridisation.
Chen YY; Yang CF; Hsu CY
J Clin Pathol; 2023 Nov; 76(11):753-756. PubMed ID: 37852628
[TBL] [Abstract] [Full Text] [Related]
8. [Efficacy of neoadjuvant therapy on HER2-positive breast cancer: a clinicopathological analysis].
Zhu P; Lyu H; Bai QM; Shui RH; Xu XL; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):907-911. PubMed ID: 37670619
[No Abstract] [Full Text] [Related]
9. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract] [Full Text] [Related]
10. HER2 Status Assessment in Endometrial Serous Carcinoma: Comparative Analysis of Two Proposed Testing and Interpretation Algorithms.
Hashem S; Zare SY; Fadare O
Int J Gynecol Pathol; 2024 Jan; 43(1):4-14. PubMed ID: 37406350
[TBL] [Abstract] [Full Text] [Related]
11. Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images.
Xue T; Chang H; Ren M; Wang H; Yang Y; Wang B; Lv L; Tang L; Fu C; Fang Q; He C; Zhu X; Zhou X; Bai Q
Sci Rep; 2023 Jun; 13(1):9746. PubMed ID: 37328516
[TBL] [Abstract] [Full Text] [Related]
12. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract] [Full Text] [Related]
13. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
[TBL] [Abstract] [Full Text] [Related]
14. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low breast cancers: Experience From a Single Academic Center.
Hu Y; Jones D; Zhao W; Tozbikian G; Wesolowski R; Parwani AV; Li Z
Mod Pathol; 2023 Jul; 36(7):100164. PubMed ID: 36967073
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Surface Decalcification With Hydrochloric Acid on the Determination of Estrogen Receptor, Progesterone Receptor, Ki67, and Human Epidermal Growth Factor Receptor 2 Expressions in Invasive breast Carcinoma Based on Immunohistochemistry and Fluorescence In Situ Hybridization.
Ping W; Xin R; Li Z; Yupeng C; Fangling S; Caihong R; Shun H; Sheng Z
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):232-238. PubMed ID: 36883948
[TBL] [Abstract] [Full Text] [Related]
16. breast cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?
Wang M; Ding Q; Gu J; Sfamenos SM; Huo L; Tang Z; Sun H; Robinson M; Tang G; Lim B; Wu Y; Albarracin CT; Sahin AA; Chen H
Clin Breast Cancer; 2023 Jun; 23(4):415-422. PubMed ID: 36878823
[TBL] [Abstract] [Full Text] [Related]
17.
Gonullu B; Angeli E; Pamoukdjian F; Bousquet G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834998
[TBL] [Abstract] [Full Text] [Related]
18. A clinicopathological study and survival analysis of 99 breast cancers with HER2/cep17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China.
Zhou S; Lv H; Li A; Li M; Zhong S; Lu H; Zhou X; Bai Q; Yang W
BMC Cancer; 2023 Jan; 23(1):84. PubMed ID: 36698078
[TBL] [Abstract] [Full Text] [Related]
19. Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer.
Wang X; Xing D; Liu Z; Zhang Y; Cheng B; Sun S; Wang Q; Dong L
Anal Bioanal Chem; 2023 Feb; 415(4):725-733. PubMed ID: 36571590
[TBL] [Abstract] [Full Text] [Related]
20. UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA; Tan PH; Quinn C; Provenzano E; Shaaban AM; Deb R; Callagy G; Starczynski J; Lee AHS; Ellis IO; Pinder SE
J Clin Pathol; 2023 Apr; 76(4):217-227. PubMed ID: 36564170
[TBL] [Abstract] [Full Text] [Related]
[Next]
